Anti-IGF2 antibody
Specifications
| Product Cat#: | AB-06-2359 |
| Product type: | Primary antibody |
| Antigen: | IGF2 |
| Immunogen: | Recombinant protein |
| Species immunized: | Rabbit |
| Isotype: | IgG |
| Applications: | Western Blot (1:500-1:2000); Immunohistochemistry (1:100-1:200); Immunocytochemistry (1:80-1:200); Immunofluorescence |
| Reactivity: | Human |
| Clonality (clone number): | Monoclonal (JJ092-3) |
| Form: | Liquid |
| Buffer: | 1*TBS (pH7.4), 1% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide. |
| Concentration: | 1 mg/ml |
| Purity: | Protein A affinity purified |
| Storage: | Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles. |
| Alternative names: | C11orf43 antibody |
| IGF 2 antibody | |
| IGF II antibody | |
| IGF-II antibody | |
| IGF2 antibody | |
| IGF2_HUMAN antibody | |
| IGFII antibody | |
| INSIGF antibody | |
| Insulin like growth factor 2 (somatomedin A) antibody | |
| Insulin like Growth Factor 2 antibody | |
| Insulin like growth factor II antibody | |
| Insulin like growth factor II precursor antibody | |
| Insulin like growth factor type 2 antibody | |
| pp9974 antibody | |
| Preptin antibody | |
| putative insulin like growth factor II associated protein antibody | |
| Somatomedin A antibody | |
| Somatomedin-A antibody |
Target information
The insulin-like growth factors possess growth-promoting activity. Major fetal growth hormone in mammals. Plays a key role in regulating fetoplacental development. IGF-II is influenced by placental lactogen. Also involved in tissue differentiation. Positively regulates myogenic transcription factor MYOD1 function by facilitating the recruitment of transcriptional coactivators, thereby controlling muscle terminal differentiation (By similarity). In adults, involved in glucose metabolism in adipose tissue, skeletal muscle and liver (Probable). Acts as a ligand for integrin which is required for IGF2 signaling (PubMed:28873464).Preptin undergoes glucose-mediated co-secretion with insulin, and acts as physiological amplifier of glucose-mediated insulin secretion. Exhibits osteogenic properties by increasing osteoblast mitogenic activity through phosphoactivation of MAPK1 and MAPK3.
Provider
Erpantech Laboratory
